FindTrial
Sign In

Study for application of ctDNA methylation and mutation detection in non-invasive diagnosis of early/mid-stage NSCLC

Study for application of ctDNA methylation and mutation detection in non-invasive diagnosis of early/mid-stage NSCLC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024028
Enrollment
Unknown
Registered
2019-06-23
Start date
2019-06-19
Completion date
Unknown
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Gold Standard:Pathological examination
Index test:ctDNA&#32
methylation&#32
and&#32
mutation&#32
detection

Sponsors

Jiangsu Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 80 years old; 2. Suspected or confirmed NSCLC patients or benign pulmonary disease patients; 3. Planned to receive surgical treatment; 4. Stage I-IIIA NSCLC or benign pulmonary disease patients; 5. Sufficient blood samples and tissue samples for analysis; 6. Signed informed consent, with good compliance.

Exclusion criteria

Exclusion criteria: 1. Recurrent NSCLC patients; 2. Lysis of plasma sample; 3. Blood sample was not processed into plasma and blood cell samples within 24 hours; 4. Pregnant or lactating patients; 5. Received any anti-tumor therapy before surgery; 6. Patients with prior cancer history.

Design outcomes

Primary

MeasureTime frame
Pathological diagnosis;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactWei Wang

Jiangsu Provincial Hospital

wangwei15261883958@163.com+86 15261883958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026